title: Spotlight on pioglitazone in type 2 diabetes mellitus.
abstract: Pioglitazone (Actos(trade mark)) is an antihyperglycemic agent that, in the presence of insulin resistance, increases hepatic and peripheral insulin sensitivity, thereby inhibiting hepatic gluconeogenesis and increasing peripheral and splanchnic glucose uptake. Pioglitazone is generally well tolerated, weight gain and edema are the most common emergent adverse events, and there are no known drug interactions between pioglitazone and other drugs. In clinical trials in patients with type 2 diabetes mellitus, pioglitazone as monotherapy, or in combination with metformin, repaglinide, insulin, or a sulfonylurea, induced both long- and short-term improvements in glycemic control and serum lipid profiles. Pioglitazone was also effective in reducing some measures of cardiovascular risk and arteriosclerosis. Pioglitazone thus offers an effective treatment option for the management of patients with type 2 diabetes.
authors: Adis International Inc., Yardley, Pennsylvania, USA.
authors: John
authors: J
authors: Waugh
authors: Gillian M
authors: GM
authors: Keating
authors: Greg L
authors: GL
authors: Plosker
authors: Stephanie
authors: S
authors: Easthope
authors: Dean M
authors: DM
authors: Robinson